Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Urology

• Publication date

  2014-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.juro.2014.06.084PMID 24996128
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guideline for the Management of Nonmuscle Invasive Bladder Cancer : ( Stages Ta , T 1 , and Tis ) : 2007 Update Bladder Cancer

  2014cited by this paper
• SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.

  2013cited by this paper
• Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression

  2013cited by this paper
• Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.

  2013cited by this paper
• Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.

  2013cited by this paper
• U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.

  2013cited by this paper
• EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

  2013influential reference
• Impact of albumin on drug delivery--new applications on the horizon.

  2012cited by this paper
• Non–Muscle-Invasive Bladder Cancer (Ta, T1, and CIS)

  2012influential reference
• Campbell-Walsh Urology

  2011cited by this paper
• A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer.

  2011cited by this paper
• The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.

  2010cited by this paper
• Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy.

  2008cited by this paper
• Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

  2007cited by this paper
• Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

  2007influential reference
• Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.

  2006cited by this paper
• Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

  2006cited by this paper
• Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

  2005cited by this paper
• Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.

  2005cited by this paper
• Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

  2005cited by this paper
• A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.

  2004cited by this paper
• Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

  2002cited by this paper
• Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

  2000cited by this paper
• Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.

  2000cited by this paper
• EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER

  2000cited by this paper
• Intravesical therapy of superficial bladder cancer.

  2000cited by this paper
• Bladder tissue pharmacokinetics of intravesical taxol

  1997cited by this paper
• Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup.

  1992cited by this paper
• Transurethral resection and intravesical therapy of superficial bladder tumors.

  1991cited by this paper
• Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.

  1987cited by this paper
• Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer.

  1984influential reference

• Sequential Intravesical Gemcitabine and Docetaxel for Non-Muscle Invasive Bladder Cancer: A Narrative Review Across Risk Groups

  2026cites this paper
• Development of Novel Intravesical Formulation for Bladder Retention Targeting Bladder Disorders.

  2025cites this paper
• Investigating the Application of Albumin-Bound Paclitaxel in the Treatment of Bladder Cancer and Its Potential Therapeutic Prospects

  2025cites this paper
• Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.

  2024cites this paper
• Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer

  2024influential citation
• Potential bladder cancer therapeutic delivery systems: a recent update

  2024cites this paper
• Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial

  2024cites this paper
• Strategies for Overcoming Immune Evasion in Bladder Cancer

  2024cites this paper
• Treatment strategies for the Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer

  2023cites this paper
• Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer

  2023cites this paper
• A systematic review of nanocarriers for treatment of urologic cancers.

  2023cites this paper
• Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems

  2023cites this paper
• Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023

  2023cites this paper
• Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.

  2023cites this paper
• New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

  2023cites this paper
• Nanoprobe-based molecular imaging for tumor stratification.

  2023cites this paper
• BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets

  2023cites this paper
• Development of novel aptamer-based targeted chemotherapy for bladder cancer.

  2022cites this paper
• Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer.

  2022cites this paper
• Role of neoadjuvant chemotherapy in the conservative management of Non-muscle invasive bladder cancer (NMIBC) T1

  2022cites this paper
• Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure

  2022cites this paper
• Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning

  2022cites this paper
• Nanomedicine for urologic cancers: diagnosis and management.

  2022cites this paper
• New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer

  2022influential citation
• New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond

  2022cites this paper
• Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer.

  2021cites this paper
• Application of nanotechnology in the diagnosis and treatment of bladder cancer

  2021cites this paper
• CUA GUIDELINE Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Full-text

  2021cites this paper
• Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.

  2021cites this paper
• Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer

  2021cites this paper
• CUAJ – CUA Guideline Bhindi et al Guideline: NMIBC management

  2021cites this paper
• The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer

  2021cites this paper
• Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer.

  2020cites this paper
• Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.

  2020cites this paper
• Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.

  2020cites this paper
• A Phase 1 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Non-muscle Invasive BCG Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.

  2020cites this paper
• Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.

  2020cites this paper
• Therapeutic management of Bacillus Calmette–Guerin refractory patients: a narrative review

  2020cites this paper
• Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?

  2020influential citation
• Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.

  2020cites this paper
• Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer

  2020cites this paper
• Intravesical Therapy for Non-muscle Invasive Urothelial Carcinoma

  2020cites this paper
• Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How To Manage Them.

  2020cites this paper
• Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

  2020cites this paper
• Advances in bladder cancer biology and therapy

  2020cites this paper
• Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage

  2019cites this paper
• Salvage therapeutic strategies for bacillus Calmette–Guerin failure

  2019cites this paper
• Current advances in BCG-unresponsive non-muscle invasive bladder cancer

  2019cites this paper
• Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer

  2019cites this paper
• Current Therapeutic Strategies in Clinical Urology.

  2018cites this paper
• Protein Aggregate Magnesium-Ammonium Phospholinoleate-Palmitoleate Anhydride Immunomodulator

  2018cites this paper
• The Role of Urologist

  2018cites this paper
• Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?

  2018cites this paper
• Advances and Perspectives in Urinary Bladder Cancer Nanotherapy

  2018cites this paper
• Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer

  2018influential citation
• Organ-Preserving Approach in Bladder Cancer: Assessment of the Current Situation

  2018cites this paper
• Urothelial Carcinoma In Situ and Treatment of Bacillus Calmette-Guérin Failures

  2018cites this paper
• Cancer Nanotherapeutics Administered by Non-conventional Routes

  2018cites this paper
• Chapter 1 Intravesical Treatment Modalities in Bladder Cancer : Current and Future Perspectives

  2018cites this paper
• Advances in risk stratification of bladder cancer to guide personalized medicine

  2018cites this paper
• Nanotechnology in Urology: History of Development and Applications in Urology

  2018cites this paper
• Treating Urothelial Bladder Cancer

  2018cites this paper
• Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.

  2018cites this paper
• Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic applications in bladder cancer

  2018cites this paper
• BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG

  2017cites this paper
• Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients

  2017cites this paper
• An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.

  2017cites this paper
• Tackling non-muscle invasive bladder cancer in the clinic

  2017cites this paper
• Non–muscle‐invasive bladder cancer: Intravesical treatments beyond Bacille Calmette‐Guérin

  2017cites this paper
• Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.

  2017cites this paper
• Alternative therapies in patients with non-muscle invasive bladder cancer.

  2017cites this paper
• Intravesical Treatment Modalities in Bladder Cancer: Current and Future Perspectives

  2017cites this paper
• Current clinical trials in non-muscle invasive bladder cancer.

  2017cites this paper
• Konservative Therapieoptionen beim nicht-muskelinvasiven Urothelkarzinom der Harnblase nach BCG-Versagen: Systematische Übersichtsarbeit

  2017cites this paper
• Welche Rolle spielt die Immunonkologie beim Urothelkarzinom aus pathologischer Sicht?

  2017cites this paper
• The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette–Guérin failures for non-muscle-invasive bladder cancer

  2016cites this paper
• Mode d’action et principes d’utilisation des instillations endovésicales

  2016cites this paper
• Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.

  2016cites this paper
• Tailoring Soft Nanoparticles for Potential Application as Drug Carriers in Bladder Cancer Chemotherapy

  2016cites this paper
• Adjuvant intravesical instillation for primary intermediate and high-risk non-muscle invasive bladder cancer: BCG versus docetaxel

  2016cites this paper
• Re: Reporter Nanoparticle that Monitors its Anticancer Efficacy in Real Time.

  2016cites this paper
• The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer

  2016cites this paper
• Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer.

  2015cites this paper
• Risk management and treatment of non-muscle-invasive bladder cancer

  2015cites this paper
• A Randomized Phase II Study of Erlotinib Plus Nab-Paclitaxel Versus Erlotinib Alone as Second-Line Therapy for Chinese Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer

  2015cites this paper
• Intravesical chemotherapy in non-muscle-invasive bladder cancer

  2015cites this paper
• Treatment options in non-muscle-invasive bladder cancer after BCG failure

  2015cites this paper
• Management of carcinoma in situ of the bladder: best practice and recent developments

  2015cites this paper
• Bacille-Calmette-Guerin non-responders: how to manage

  2015cites this paper
• A primer on clinical trial design.

  2015cites this paper